The traditional approach to drug design has produced few drugs and
proves to have a very low or even negative return on investment. Common Pharma
has a new approach to drug design that produces safer, lower cost and more
effective medications. The chemotherapeutic agents for both infectious and
cancer indications have been very toxic with very low rate of efficacy, high
cost and small improvement in life expectancy.
|